bb3

BA 1 acetate is a potent bombesin receptor agonist (IC50 values are 0.26, 1.55 and 2.52 nM for BB1, BB2 and BB3 respectively). Enhances glucose transport in obese and diabetic primary myocytes. Also stimulates NCI-H1299 lung cancer cell proliferation in v

PBB3 is a tau-specific PET tracer.

CBB3001 is a selective lysine-specific histone demethylase LSD1 inhibitor.

KRIBB3 is novel and potent microtubule inhibitor with potential anticancer activity. KRIBB3 has anti-migratory and anti-invasive activities in MDA-MB-231 cells. KRIBB3 inhibits tumor cell migration and invasion by blocking protein kinase C-dependent phosphorylation of Hsp27 through its direct binding to Hsp27.

Anti-ERBB3/HER3 (SGP1) is a human monoclonal antibody (mAb) targeting ERBB3/HER3. It inhibits Neuregulin-stimulated growth of cultured breast cancer cells and can be utilized in breast cancer research.

Anti-HER3/ERBB3 Antibody (4V862) is a Rabbit IgG monoclonal antibody targeting Human HER3/ERBB3.

Anti-HER3/ERBB3 Antibody (1P393) is a Mouse IgG1 monoclonal antibody targeting Human HER3/ERBB3.

Anti-HER3/ERBB3 Antibody (2W239) is a mouse (varialbe region) / human (kappa / IgG1 constant) chimeric monoclonal antibody targeting Human HER3/ERBB3.

Anti-HER3/ERBB3 Antibody (2Y512) is a mouse (varialbe region) / human (kappa / IgG1 constant) chimeric monoclonal antibody targeting Human HER3/ERBB3.

Anti-ERBB3/HER3 (29Z6) is an antibody inhibitor targeting human ERBB3/HER3.

TX1-85-1 induces partial degradation of Her3 protein and attenuates Her3-dependent signaling. TX1-85-1 is an irreversible Her3 inhibitor (IC50: 23 nM). TX1-85-1 is also the first selective Her3 ligand, which forms a covalent bond with Cys721 located in th

WS3, a β cell proliferation inducer, regulates Erb3 binding protein-1 (EBP1) and the IκB kinase pathway.

WS6, a β cell proliferation inducer, regulates Erb3 binding protein-1 (EBP1) and the IκB kinase pathway.

BB-3497, a potent inhibitor of Escherichia coli peptide deformylase, has antibacterial activity both in vitro and in vivo.

PD 158780 reversibly inhibits auto and transphosphorylation of all four members of the ErbB receptor superfamily: EGFR, ErbB2, ErbB3, and ErbB4 (IC50s: 8μM, 49 nM, 52 nM, and 52 nM in cell assay).

GNLPT-IN-1 is an inhibitor of gram-negative lipoprotein trafficking.

GR-95030X is a a novel HMG-CoA reductase inhibitor.

Lumretuzumab (RG-7116) is a humanized anti-HER3 monoclonal antibody with antitumor activity for the study of advanced HER3-positive solid tumors and breast cancer.

Barecetamab (ISU-104) is a humanized monoclonal antibody against tyrosine protein kinase ErbB3 with anticancer activity for use in investigational stage malignant solid tumors.

Patritumab-MMAE , an Anti-ERBB3/HER3 Reference Antibody, is produced in CHO cells. This antibody comprises a heavy chain of type huIgG1 and a light chain of type hukappa, with a predicted molecular weight (MW) of 150 kDa.

DSO-5a, a potent and selective orally active BB3 agonist, is a DMAKO-00 derivative that enhances ppar-γ activity via BB3 and stimulates ERK1/2 phosphorylation. It is utilized in diabetes-related research [1].

Potent bombesin receptor agonist (IC50 values are 0.26, 1.55 and 2.52 nM for BB1, BB2 and BB3 respectively). Enhances glucose transport in obese and diabetic primary myocytes. Also stimulates NCI-H1299 lung cancer cell proliferation in vitro.

[D-Cys6,Asn7,D-Ala11,Cys14]-Bombesin (6-14) is a synthetic peptide that functions as a non-selective bombesin receptor agonist. It exhibits pEC50 values of 8.06 for neuromedin B-preferential bombesin receptor (BB1), 8.69 for gastrin-releasing peptide-preferential bombesin receptor (BB2), and 6.71 for the orphan receptor (BB3). This compound is utilized in studies related to bombesin receptor-associated conditions, including cancer and neurological disorders.